vs

Side-by-side financial comparison of Star Holdings (STHO) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

Zymeworks Inc. is the larger business by last-quarter revenue ($27.6M vs $25.4M, roughly 1.1× Star Holdings). Zymeworks Inc. runs the higher net margin — -71.0% vs -75.5%, a 4.5% gap on every dollar of revenue. On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs -22.6%).

Blue Star Ltd is an Indian multinational home appliances company, headquartered in Mumbai. It specializes in air conditioning, commercial refrigeration and MEP. It is the country's second largest homegrown player in the air conditioning space.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

STHO vs ZYME — Head-to-Head

Bigger by revenue
ZYME
ZYME
1.1× larger
ZYME
$27.6M
$25.4M
STHO
Growing faster (revenue YoY)
ZYME
ZYME
+95.2% gap
ZYME
72.6%
-22.6%
STHO
Higher net margin
ZYME
ZYME
4.5% more per $
ZYME
-71.0%
-75.5%
STHO

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
STHO
STHO
ZYME
ZYME
Revenue
$25.4M
$27.6M
Net Profit
$-19.1M
$-19.6M
Gross Margin
Operating Margin
-91.7%
-80.1%
Net Margin
-75.5%
-71.0%
Revenue YoY
-22.6%
72.6%
Net Profit YoY
81.3%
34.3%
EPS (diluted)
$-1.52
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
STHO
STHO
ZYME
ZYME
Q4 25
$25.4M
Q3 25
$28.1M
$27.6M
Q2 25
$42.1M
$48.7M
Q1 25
$14.6M
$27.1M
Q4 24
$32.8M
$31.0M
Q3 24
$24.6M
$16.0M
Q2 24
$30.6M
$19.2M
Q1 24
$25.4M
$10.0M
Net Profit
STHO
STHO
ZYME
ZYME
Q4 25
$-19.1M
Q3 25
$1.8M
$-19.6M
Q2 25
$-39.3M
$2.3M
Q1 25
$-7.6M
$-22.6M
Q4 24
$-102.6M
$-23.5M
Q3 24
$91.9M
$-29.9M
Q2 24
$-27.1M
$-37.7M
Q1 24
$-49.0M
$-31.7M
Operating Margin
STHO
STHO
ZYME
ZYME
Q4 25
-91.7%
Q3 25
1.0%
-80.1%
Q2 25
-94.5%
-1.4%
Q1 25
-55.0%
-94.5%
Q4 24
-314.1%
-71.6%
Q3 24
-213.8%
Q2 24
-91.5%
-222.9%
Q1 24
-192.6%
-376.9%
Net Margin
STHO
STHO
ZYME
ZYME
Q4 25
-75.5%
Q3 25
6.4%
-71.0%
Q2 25
-93.5%
4.8%
Q1 25
-52.0%
-83.5%
Q4 24
-313.1%
-75.8%
Q3 24
374.3%
-186.6%
Q2 24
-88.8%
-195.8%
Q1 24
-192.6%
-315.6%
EPS (diluted)
STHO
STHO
ZYME
ZYME
Q4 25
$-1.52
Q3 25
$0.14
$-0.26
Q2 25
$-2.95
$0.03
Q1 25
$-0.57
$-0.30
Q4 24
$-7.69
$-0.32
Q3 24
$6.90
$-0.39
Q2 24
$-2.04
$-0.49
Q1 24
$-3.68
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
STHO
STHO
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$50.1M
$64.8M
Total DebtLower is stronger
$268.7M
Stockholders' EquityBook value
$251.8M
$320.1M
Total Assets
$570.2M
$397.3M
Debt / EquityLower = less leverage
1.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
STHO
STHO
ZYME
ZYME
Q4 25
$50.1M
Q3 25
$40.6M
$64.8M
Q2 25
$44.2M
$98.3M
Q1 25
$30.3M
$76.2M
Q4 24
$35.0M
$66.1M
Q3 24
$45.0M
$122.4M
Q2 24
$48.3M
$71.0M
Q1 24
$45.7M
$114.8M
Total Debt
STHO
STHO
ZYME
ZYME
Q4 25
$268.7M
Q3 25
$259.3M
Q2 25
$245.4M
Q1 25
$231.5M
Q4 24
$217.3M
Q3 24
$201.2M
Q2 24
$197.2M
Q1 24
$195.0M
Stockholders' Equity
STHO
STHO
ZYME
ZYME
Q4 25
$251.8M
Q3 25
$275.4M
$320.1M
Q2 25
$276.1M
$334.5M
Q1 25
$316.1M
$325.0M
Q4 24
$324.3M
$338.8M
Q3 24
$427.5M
$367.0M
Q2 24
$335.3M
$406.2M
Q1 24
$362.4M
$438.0M
Total Assets
STHO
STHO
ZYME
ZYME
Q4 25
$570.2M
Q3 25
$595.9M
$397.3M
Q2 25
$589.9M
$408.4M
Q1 25
$618.2M
$425.5M
Q4 24
$608.7M
$463.1M
Q3 24
$696.5M
$487.2M
Q2 24
$601.0M
$515.6M
Q1 24
$622.9M
$553.8M
Debt / Equity
STHO
STHO
ZYME
ZYME
Q4 25
1.07×
Q3 25
0.94×
Q2 25
0.89×
Q1 25
0.73×
Q4 24
0.67×
Q3 24
0.47×
Q2 24
0.59×
Q1 24
0.54×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
STHO
STHO
ZYME
ZYME
Operating Cash FlowLast quarter
$-11.7M
$-31.4M
Free Cash FlowOCF − Capex
$-31.8M
FCF MarginFCF / Revenue
-115.2%
Capex IntensityCapex / Revenue
1.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
STHO
STHO
ZYME
ZYME
Q4 25
$-11.7M
Q3 25
$5.3M
$-31.4M
Q2 25
$-2.6M
$12.1M
Q1 25
$-6.3M
$-3.4M
Q4 24
$-31.3M
$-41.5M
Q3 24
$-3.8M
$-5.9M
Q2 24
$-6.4M
$-25.0M
Q1 24
$-14.2M
$-37.7M
Free Cash Flow
STHO
STHO
ZYME
ZYME
Q4 25
Q3 25
$-31.8M
Q2 25
$11.6M
Q1 25
$-3.4M
Q4 24
$-41.8M
Q3 24
$-6.8M
Q2 24
$-25.6M
Q1 24
$-37.9M
FCF Margin
STHO
STHO
ZYME
ZYME
Q4 25
Q3 25
-115.2%
Q2 25
23.7%
Q1 25
-12.6%
Q4 24
-134.8%
Q3 24
-42.4%
Q2 24
-133.0%
Q1 24
-377.5%
Capex Intensity
STHO
STHO
ZYME
ZYME
Q4 25
Q3 25
1.5%
Q2 25
1.1%
Q1 25
0.1%
Q4 24
1.0%
Q3 24
5.6%
Q2 24
3.1%
Q1 24
1.8%
Cash Conversion
STHO
STHO
ZYME
ZYME
Q4 25
Q3 25
2.95×
Q2 25
5.21×
Q1 25
Q4 24
Q3 24
-0.04×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

STHO
STHO

Land Development$13.0M51%
Other Income Revenue$9.3M37%
Operating Lease Income$2.0M8%
Other$1.2M5%

ZYME
ZYME

Segment breakdown not available.

Related Comparisons